Assessment of lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the lung

被引：36

作者：

Shilpi S. ^{[1
,2
]}

Vimal V.D. ^{[1
]}

Soni V. ^{[1
]}

机构：

[1] Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar, Madhya Pradesh

[2] Ravishankar College of Pharmacy, Bhopal, Madhya Pradesh

来源：

Progress in Biomaterials | 2015年 / 4卷 / 1期

关键词：

Biodistribution; Drug delivery; Lactoferrin; Lung targeting; SLNs;

D O I：

10.1007/s40204-015-0037-z

中图分类号：

学科分类号：

摘要：

The aim of the present study was to develop a target oriented drug delivery system for the lungs. Lactoferrin (Lf)-coupled solid lipid nanoparticles (SLNs) bearing rifampicin was prepared by a solvent injection method. The prepared nanoparticles were characterized for shape, particle size, polydispersity and percentage drug entrapment. An optimized formulation was then studied for its in vivo performance in animals and to determine its targeting efficiency. It was observed that, upon coupling with Lf, the size of SLNs increased while the percent entrapment efficiency decreases. In in vitro release, determined by a dialysis technique, analysis showed that uncoupled SLNs exhibited higher drug release as compared to coupled SLNs. An in vivo biodistribution study shows 47.7 ±0.4 drug uptakes by the lungs, which was 3.05 times higher in comparison to uncoupled SLNs. These biodistribution studies are further supported by the fluorescence study that revealed enhanced uptake of Lf-coupled SLNs in the lung. From the presented results, it can be concluded that Lf- coupled SLNs enhanced drug uptake in the lung. Moreover, lactoferrin is an efficient molecule that can be used for targeting active agents directly to the lung. © The Author(s) 2015.

引用

页码：55 / 63

页数：8

共 33 条

[1]

Allen T.M., Ligand targeted therapeutic in anticancer therapy, Nat Rev, 2, (2002)

[2]

Alpiaz A., Mezzena M., Scatturin A., Scalia S., Solid lipid microparticles for the stability enhancement of the polar drug N-6-cyclopentyladenosine, Int J Pharm, 355, 1-2, pp. 81-86, (2008)

[3]

Anisimova Y.V., Gelperina S.I., Peloquin C.A., Heifets L.B., Nanoparticles as antituberculosis drugs carriers: Effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages, J Nanopart Res, 2, pp. 165-171, (2000)

[4]

Baek J.S., Cho C.W., 2-Hydroxypropyl-b-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells, J Pharm Pharmacol, 65, 1, pp. 72-78, (2013)

[5]

Calleja I., Blanco-Prieto M.J., Ruz N., Renedo M.J., Dios-Vieitez M.C., High-performance liquid-chromatographic determination of Rifampicin in plasma and tissues, J Chromatogr A, 1031, pp. 289-294, (2004)

[6]

Carneiro G., Silva E.L., Pacheco L.A., De Souza-Fagundes E.M., Correa N.C., De Goes A.M., Et al., Formation of ion pairing as an alternative to improve encapsulation and anticancer activity of all-trans retinoic acid loaded in solid lipid nanoparticles, Int J Nanomed, 7, pp. 6011-6020, (2012)

[7]

Deol P., Khuller G.K., Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice, Biochim Biophys Acta, 1334, pp. 161-172, (1997)

[8]

Elfinger M., Maucksch C., Rudolph C., Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells, Biomaterials, 28, pp. 3448-3455, (2007)

[9]

Fry D.W., Rapid separation of low molecular weight solutes from liposomes without dilution, J Anal Biochem, 90, pp. 803-807, (1978)

[10]

Gupta Y., Jain A., Jain S.K., Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain, J Pharm Pharmacol, 59, pp. 1-6, (2007)

← 1 2 3 4 →